Health Catalyst (HCAT) to Post Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.02 per share and revenue of $69.0030 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Monday, May 11th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.01. The firm had revenue of $70.76 million during the quarter, compared to analysts’ expectations of $69.24 million. Health Catalyst had a negative return on equity of 3.52% and a negative net margin of 87.69%. On average, analysts expect Health Catalyst to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Health Catalyst Stock Up 0.9%

Shares of HCAT opened at $2.16 on Thursday. The business’s 50 day moving average is $1.86 and its 200 day moving average is $1.71. The company has a market capitalization of $159.60 million, a PE ratio of -0.58 and a beta of 1.56. Health Catalyst has a 12-month low of $0.96 and a 12-month high of $3.95. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 1.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HCAT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Health Catalyst by 7.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after purchasing an additional 2,624 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Health Catalyst by 19.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock worth $100,000 after buying an additional 4,341 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after acquiring an additional 6,832 shares during the last quarter. Invesco Ltd. grew its stake in Health Catalyst by 6.5% during the 4th quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock valued at $283,000 after acquiring an additional 7,186 shares in the last quarter. Finally, Barclays PLC grew its stake in Health Catalyst by 7.3% during the 4th quarter. Barclays PLC now owns 148,186 shares of the company’s stock valued at $354,000 after acquiring an additional 10,100 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Health Catalyst from $1.00 to $1.75 and gave the company an “equal weight” rating in a report on Friday, June 26th. Cantor Fitzgerald reissued a “neutral” rating on shares of Health Catalyst in a report on Monday, May 11th. Weiss Ratings upgraded shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Citigroup reaffirmed a “neutral” rating on shares of Health Catalyst in a research note on Thursday, July 23rd. Finally, Canaccord Genuity Group lifted their price target on shares of Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.93.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.